WO2023281021 - ENGINEERED EXTRACELLULAR VESICLES FOR INTRACELLULAR DELIVERY
National phase entry is expected:
Publication Number
WO/2023/281021
Publication Date
12.01.2023
International Application No.
PCT/EP2022/068998
International Filing Date
07.07.2022
Title **
[English]
ENGINEERED EXTRACELLULAR VESICLES FOR INTRACELLULAR DELIVERY
[French]
VÉSICULES EXTRACELLULAIRES MODIFIÉES POUR ADMINISTRATION INTRACELLULAIRE
Applicants **
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd, DK
Inventors
GUO, Tingqing
Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road
Beijing, Anhui 102206, CN
LYU, Ying
Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road
Beijing, Anhui 102206, CN
HAN, Qifeng
Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road
Beijing, Anhui 102206, CN
Priority Data
PCT/CN2021/105335
08.07.2021
CN
202210755641.2
30.06.2022
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1261 | |
| EPO | Filing, Examination | 4846 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 607 | |
| USA | Filing, Examination | 5710 |
Total: 13015 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to engineered extracellular vesicles. More specifically, the present invention relates to an isolated EV comprising a fusogenic protein, a binding moiety to a cell membrane protein, and a molecule of interest, wherein the fusogenic protein and the binding moiety are displayed on the EV separately. The EV disclosed in the present invention shows improved intracellular delivery efficiency. The present invention also relates to a pharmaceutical composition comprising the EV and a method of delivering a molecule of interest to a recipient cell.[French]
La présente invention concerne des vésicules extracellulaires modifiées. Plus spécifiquement, la présente invention concerne un VE isolée comprenant une protéine fusogène, une fraction de liaison à une protéine de membrane cellulaire, et une molécule d'intérêt, la protéine fusogène et la fraction de liaison étant exposées séparément sur la VE. La VE décrite dans la présente invention présente une efficacité d'administration intracellulaire améliorée. La présente invention concerne également une composition pharmaceutique comprenant la VE et un procédé d'administration d'une molécule d'intérêt à une cellule receveuse.